Wednesday, August 30, 2023 Daily Archives

Problem-solving in upstream bioprocessing

by

Find information and advices about upstream bioprocess development for cell and gene therapy applications on our website! The field of cell and gene therapies is a new and emerging category of seeking methods to cure diseases by restoring or reconditioning cells or genes. Research and development in this field are vastly expanding and nowadays, progressively more cell and gene therapy applications are making its way through R&D towards clinical trials and beyond. Eppendorf Bioprocess supports you in evolving a scientific…

August 30, 2023

Resilience revisits the Middle East with Saudi Arabia JV

by

CDMO Resilience has inked a joint venture with Saudi Arabian drug company Lifera to build a drug product manufacturing facility in Riyadh. The contract development manufacturing organization (CDMO) will help to design and construct the cGMP facility in Riyadh, Saudi Arabia, which will be operated by local pharma company Lifera. “The joint venture opportunity represents a continued expansion of our international strategy as we seek to benefit patients worldwide by advancing biopharmaceutical supply chains,” Resilience CEO Rahul Singhvi said. Resilience…

August 30, 2023

Cabaletta eyes commercialization through WuXi ATU expansion

by

The expanded agreement sees CDMO WuXi manufacture CAR-T therapy CABA-201, in preparation for commercialization and planned clinical trials. Calabetta Bio and contract development manufacturing organization (CDMO) WuXi Advanced Therapies (WuXi ATU) initially partnered two years ago for the GMP manufacturing of cell therapies. Under the extended agreement, WuXi ATU will provide GMP manufacturing of CABA-201, a fully human CD19- chimeric antigen receptor (CAR) T-cell investigational therapy. The investigational therapy aims to treat individuals with systemic lupus erythematosus and idiopathic inflammatory…

August 30, 2023